MCID: RLP008
MIFTS: 27

Relapsed/refractory Diffuse Large B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Relapsed/refractory Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Relapsed/refractory Diffuse Large B-Cell Lymphoma:

Name: Relapsed/refractory Diffuse Large B-Cell Lymphoma 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0080192

Summaries for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Disease Ontology : 12 A diffuse large B-cell lymphoma characterized by less than 50 percent decrease in lesion size with induction therapy or the appearance of new lesions or the appearance of new lesions after attainment of complete remission.

MalaCards based summary : Relapsed/refractory Diffuse Large B-Cell Lymphoma is related to diffuse large b-cell lymphoma and b-cell lymphomas. An important gene associated with Relapsed/refractory Diffuse Large B-Cell Lymphoma is FOXP1 (Forkhead Box P1), and among its related pathways/superpathways are B cell receptor signaling pathway (KEGG) and Dendritic Cells Developmental Lineage Pathway. The drugs Cisplatin and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and endothelial.

Related Diseases for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Diseases related to Relapsed/refractory Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 diffuse large b-cell lymphoma 31.2 FOXP1 IRF4
2 b-cell lymphomas 30.9 FOXP1 IRF4
3 lymphoma 10.7
4 carney complex, type 1 10.1
5 caronte 10.1
6 mantle cell lymphoma 10.1
7 primary mediastinal large b-cell lymphoma 10.0 FOXP1 IRF4
8 marginal zone b-cell lymphoma 9.9 FOXP1 IRF4
9 colon lymphoma 9.9 CD19 IRF4
10 leukemia, acute lymphoblastic 3 9.9 CD19 FOXP1
11 bladder lymphoma 9.8 CD19 GBA
12 lymphoma, mucosa-associated lymphoid type 9.8 CD19 FOXP1 IRF4
13 myeloma, multiple 9.7 CARTPT CD19 IRF4
14 leukocyte disease 9.7 CD19 GBA IRF4
15 lymphoma, non-hodgkin, familial 9.6 CD19 GBA IRF4

Graphical network of the top 20 diseases related to Relapsed/refractory Diffuse Large B-Cell Lymphoma:



Diseases related to Relapsed/refractory Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Drugs & Therapeutics for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Drugs for Relapsed/refractory Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 2,Phase 3 15663-27-1 2767 441203 84093
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 1177-87-3
3
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3 147-94-4 6253
4
Etoposide Approved Phase 4,Phase 1,Phase 2 33419-42-0 36462
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
6 BB 1101 Phase 4,Phase 2,Phase 3
7 Etoposide phosphate Phase 4,Phase 1,Phase 2
8 tyrosine Phase 4,Phase 1,Phase 2
9 Endothelial Growth Factors Phase 4
10 Mitogens Phase 4
11
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
12
Bortezomib Approved, Investigational Phase 2, Phase 3,Phase 1 179324-69-7 387447 93860
13
Vincristine Approved, Investigational Phase 1, Phase 2 57-22-7, 2068-78-2 5978
14
Lenalidomide Approved Phase 1, Phase 2,Phase 2 191732-72-6 216326
15
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
16
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
17
Doxorubicin Approved, Investigational Phase 1, Phase 2,Phase 2 23214-92-8 31703
18 Blinatumomab Approved, Investigational Phase 2 853426-35-4
19
Everolimus Approved Phase 2 159351-69-6 6442177
20
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
21
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
22
Ofatumumab Approved Phase 2 679818-59-8 6918251
23
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
24
Mesna Approved, Investigational Phase 2,Phase 1 3375-50-6 598
25
Ifosfamide Approved Phase 2,Phase 1 3778-73-2 3690
26
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
27
Gemcitabine Approved Phase 2 95058-81-4 60750
28
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
29
Nivolumab Approved Phase 1, Phase 2,Phase 2 946414-94-4
30
Idelalisib Approved Phase 2 870281-82-6
31
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
32
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
33
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
34
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
35
Doxil Approved June 1999 Phase 1, Phase 2,Phase 2 31703
36 Adjuvants, Immunologic Phase 2
37 Immunologic Factors Phase 2,Phase 1
38 Angiogenesis Inhibitors Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 2,Phase 1
40 Interleukin-12 Phase 2
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2,Phase 2
42 Antirheumatic Agents Phase 1, Phase 2,Phase 2
43 Hormones Phase 1, Phase 2,Phase 2
44 Immunosuppressive Agents Phase 1, Phase 2,Phase 2
45 Hormone Antagonists Phase 1, Phase 2,Phase 2
46 Topoisomerase Inhibitors Phase 1, Phase 2,Phase 2
47 Antibiotics, Antitubercular Phase 1, Phase 2,Phase 2
48 Anti-Infective Agents Phase 1, Phase 2,Phase 2
49 Antineoplastic Agents, Alkylating Phase 1, Phase 2,Phase 2
50 Antineoplastic Agents, Hormonal Phase 1, Phase 2,Phase 2

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03376958 Phase 4 Apatinib
2 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Unknown status NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
3 Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03391466 Phase 3 Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.;Cyclophosphamide;Fludarabine
4 NM-IL-12 (rHuIL‐12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy Unknown status NCT02544724 Phase 2
5 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma Unknown status NCT02142049 Phase 1, Phase 2 Ibrutinib;Part 1: Dose Level 1
6 A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Unknown status NCT01676558 Phase 2 131I-rituximab
7 CyBeR Association in Relapsed/Refractory DLBCL Unknown status NCT02758925 Phase 2 Rituximab;Bendamustine;Cytarabine
8 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT01741792 Phase 2 Blinatumomab
9 Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma Completed NCT01118845 Phase 2 SyB L-0501;Rituximab
10 Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Completed NCT00869999 Phase 2 Everolimus;rituximab
11 Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT02391116 Phase 2 Copanlisib (Aliqopa, BAY80-6946)
12 Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Completed NCT01470456 Phase 2 SAR3419;rituximab
13 Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT00823719 Phase 2 ofatumumab + ICE;ofatumumab + DHAP
14 AZD1152 in Diffuse Large B-cell Lymphoma Completed NCT01354392 Phase 1, Phase 2 AZD1152
15 Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT02412267 Phase 2 O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
16 To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL Completed NCT02624492 Phase 2 BI 836826;GemOx;Rituximab;GemOx
17 Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT01555541 Phase 2 Ofatumumab;Etoposide;Cytarabine
18 RICE-ibrutinib in Relapsed DLBCL Recruiting NCT02955628 Phase 2 Ibrutinib-RICE
19 Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Recruiting NCT03305445 Phase 1, Phase 2 Ipilimumab;Nivolumab
20 Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma Recruiting NCT01959698 Phase 1, Phase 2 Carboplatin;Carfilzomib;Etoposide;Ifosfamide
21 Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma Recruiting NCT03576443 Phase 2 Idelalisib
22 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations Recruiting NCT02674750 Phase 2 CUDC-907
23 Rituximab, Bendamustine and Melphalan Chemo-immunotherapy Followed by Reinfusion of One's Own Stem Cell for Treatment of B-cell Lymphoma in Elderly Patients Recruiting NCT03352765 Phase 1, Phase 2 rituximab;bendamustine;melphalan
24 BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) Recruiting NCT03520920 Phase 2 BGB-3111
25 A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting NCT02227251 Phase 2 Selinexor
26 An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma Active, not recruiting NCT02752204 Phase 2 AZD 2014;Rituximab
27 Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting NCT02077166 Phase 1, Phase 2 Ibrutinib;Lenalidomide;Rituximab
28 A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Active, not recruiting NCT02399085 Phase 2 MOR00208;Lenalidomide
29 Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not yet recruiting NCT03719989 Phase 2 azacitidine plus R-GDP
30 Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Not yet recruiting NCT03484819 Phase 2 Copanlisib
31 Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Terminated NCT01282476 Phase 2 Panobinostat with Rituximab
32 Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated NCT00978432 Phase 2 RAD001;LBH589;Doublet (RAD001 and LBH589)
33 Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Terminated NCT00968331 Phase 2 Lenalidomide plus Rituximab
34 Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment Terminated NCT00851552 Phase 2 bortezomib;pegylated liposomal doxorubicin hydrochloride
35 Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients Terminated NCT02374424 Phase 2 GA101_DHAP
36 Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment Withdrawn NCT00829205 Phase 1, Phase 2 carboplatin;etoposide;ifosfamide
37 Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma Completed NCT01226849 Phase 1 bortezomib, rituximab, ifosphamide, etoposide, carboplatin
38 Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03450343 Phase 1 Oral azacitidine;R-ICE
39 A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting NCT03136497 Phase 1 ABT-199;Ibrutinib;Rituximab
40 A Trial of Radiotherapy and Durvalumab in DLBCL Recruiting NCT03610061 Phase 1 Durvalumab
41 Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Recruiting NCT03440567 Phase 1 Avelumab;Carboplatin;Etoposide Phosphate;Ibrutinib;Ifosfamide
42 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Recruiting NCT03571828 Phase 1 AMG 562
43 A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. Recruiting NCT02417285 Phase 1 Obinutuzumab;CC-122
44 A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 Recruiting NCT03255096 Phase 1 RO6870810;Venetoclax;Rituximab
45 Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) Recruiting NCT02658968 Phase 1 Betalutin
46 Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients Recruiting NCT03630159 Phase 1 Pembrolizumab
47 Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting NCT03064867 Phase 1 Venetoclax;RICE
48 A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Active, not recruiting NCT02220842 Phase 1 Atezolizumab;Obinutuzumab;Tazemetostat
49 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma Terminated NCT02082977 Phase 1 GSK2816126
50 A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT00301301 Gemcitabine;Cisplatinum;Rituximab

Search NIH Clinical Center for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Genetic Tests for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Anatomical Context for Relapsed/refractory Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Relapsed/refractory Diffuse Large B-Cell Lymphoma:

41
B Cells, T Cells, Endothelial, Colon

Publications for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Articles related to Relapsed/refractory Diffuse Large B-Cell Lymphoma:

(show all 17)
# Title Authors Year
1
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. ( 29413279 )
2018
2
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. ( 29914976 )
2018
3
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. ( 29616865 )
2018
4
Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant. ( 29623179 )
2018
5
How I manage patients with relapsed/refractory diffuse large B cell lymphoma. ( 29808921 )
2018
6
Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab ( 29479962 )
2018
7
A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma. ( 29097500 )
2018
8
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ( 28060891 )
2017
9
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. ( 28860342 )
2017
10
Blinatumomab in relapsed/refractory diffuse large B cell lymphoma. ( 28779352 )
2017
11
Predictive value of [(18)F]fluoro-2-deoxy-d-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant. ( 23617323 )
2013
12
Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report. ( 23432722 )
2013
13
Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. ( 23813874 )
2013
14
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. ( 23620452 )
2013
15
Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone, and bleomycin in patients with relapsed/refractory diffuse large B cell lymphoma. ( 24070424 )
2013
16
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. ( 23835718 )
2013
17
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. ( 21947824 )
2011

Variations for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Expression for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Relapsed/refractory Diffuse Large B-Cell Lymphoma.

Pathways for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Pathways related to Relapsed/refractory Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.33 CD19 IRF4
2 10.49 CD19 IRF4

GO Terms for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Biological processes related to Relapsed/refractory Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to starvation GO:0009267 8.62 CARTPT GBA

Sources for Relapsed/refractory Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....